Compare · IMDX vs NNNN
IMDX vs NNNN
Side-by-side comparison of Insight Molecular Diagnostics Inc. (IMDX) and Anbio Biotechnology (NNNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMDX and NNNN operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $2.37B, about 13.6x IMDX ($174.4M).
- Over the past year, IMDX is up 42.9% and NNNN is down 8.1% - IMDX leads by 51.0 points.
- IMDX has been more active in the news (8 items in the past 4 weeks vs 2 for NNNN).
PerformanceIMDX+56.43%NNNN-8.13%
2025-06-24+0.00%2026-06-22
- Company
- Insight Molecular Diagnostics Inc.
- Anbio Biotechnology
- Price
- $5.35-1.83%
- $16.73-3.35%
- Market cap
- $174.4M
- $2.37B
- 1M return
- -13.50%
- -45.13%
- 1Y return
- +42.86%
- -8.13%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 8
- 2
- Recent ratings
- 0
- 0
Latest IMDX
- iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry
- Director Silverman Lou was granted 26,943 shares, increasing direct ownership by 74% to 63,507 units (SEC Form 4)
- Director Last Andrew J. was granted 26,943 shares, increasing direct ownership by 68% to 66,452 units (SEC Form 4)
- Director Arno Andrew was granted 32,331 shares, increasing direct ownership by 24% to 168,885 units (SEC Form 4)
- IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
- iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
- SEC Form 10-Q filed by Insight Molecular Diagnostics Inc.
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NNNN
- SEC Form 3 filed by new insider Zhang Michael W.C
- SEC Form 3 filed by new insider Hsu David H
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany